1. Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
- Author
-
Cook, Linda S, Pestak, Claire R, Leung, Andy CY, Steed, Helen, Nation, Jill, Swenerton, Kenneth, Gallagher, Richard, Magliocco, Anthony, Köbel, Martin, Brooks-Wilson, Angela, Le, Nhu, and Köbel, Martin
- Abstract
Background: Combined oral contraceptive (COC) use reduces epithelial ovarian cancer (EOC) risk. However, little is known about risk with COC use before the first full-term pregnancy (FFTP).Methods: This Canadian population-based case-control study (2001-2012) included 854 invasive cases/2139 controls aged ⩾40 years who were parous and had information on COC use. We estimated odds ratios (aORs) and 95% confidence intervals (CI) adjusted for study site, age, parity, breastfeeding, age at FFTP, familial breast/ovarian cancer, tubal ligation, and body mass.Results: Among parous women, per year of COC use exclusively before the FFTP was associated with a 9% risk reduction (95% CI=0.86-0.96). Results were similar for high-grade serous and endometrioid/clear cell EOC. In contrast, per year of use exclusively after the FFTP was not associated with risk (aOR=0.98, 95% CI=0.95-1.02).Conclusions: Combined oral contraceptive use before the FFTP may provide a risk reduction that remains for many years, informing possible prevention strategies. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF